{"transactions":[{"id":331644,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2024-08-05T22:25:19.000Z","date":"2024-08-01","kind":"other","planned":false,"acquired":false,"shares":27349211,"price":45,"value":1230714495.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"AbbVie\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of AbbVie upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000078003-24-000169","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000169/primary_doc.xml","form_type":"4"}},{"id":350903,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-03-23T20:14:26.000Z","date":"2023-03-17","kind":"purchase","planned":false,"acquired":true,"shares":1811594,"price":2.76,"value":4999999.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities were issued under that certain first amendment dated March 16, 2023 to the Amended and Restated License Agreement dated October 14, 2022 between the Reporting Person and the Issuer, pursuant to which the Issuer agreed to issue to the Reporting Person such number of shares of common stock equivalent to $5.0 million at a per share price equal to the closing price of the Issuer's common stock on the business day when the closing price of the Issuer's common stock on the Nasdaq Global Select Market is at or above $2.46 per share on any day between March 16, 2023 and a date that is within 180 days following October 6, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 17, 2023, the closing price of the Issuer's common stock on the Nasdaq Global Select Market was $2.76 per share."}],"balance_after":5952263,"source":{"system":"sec-edgar","filing":"0000078003-23-000052","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000052/primary_doc.xml","form_type":"4/A","original_submission_date":"2023-03-21"}},{"id":350952,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-03-21T22:07:27.000Z","date":"2023-03-17","kind":"purchase","planned":false,"acquired":true,"shares":1811594,"price":2.76,"value":4999999.44,"ownership":{"direct":true},"balance_after":5952263,"source":{"system":"sec-edgar","filing":"0000078003-23-000050","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000050/primary_doc.xml","form_type":"4"}},{"id":382719,"issuer":{"id":879,"kind":"organization","name":"BioAtla, Inc.","symbol":"BCAB"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2020-12-22T22:58:52.000Z","date":"2020-12-18","kind":"exercise","acquired":false,"shares":2238090,"ownership":{"direct":false,"nature":"See Footnote (2)"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Series D Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Series D Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Series D Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Series D Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer Inc."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2238090},"source":{"system":"sec-edgar","filing":"0000078003-20-000080","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000080/primary_doc.xml","form_type":"4"}},{"id":382718,"issuer":{"id":879,"kind":"organization","name":"BioAtla, Inc.","symbol":"BCAB"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-22T22:58:52.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":2238090,"ownership":{"direct":false,"nature":"See Footnote(2)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Series D Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer Inc."}],"balance_after":2238090,"source":{"system":"sec-edgar","filing":"0000078003-20-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000080/primary_doc.xml","form_type":"4"}},{"id":383929,"issuer":{"id":3277,"kind":"organization","name":"Viatris Inc","symbol":"VTRS"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.01 per share","published_at":"2020-11-16T22:23:34.000Z","date":"2020-11-16","kind":"other","acquired":false,"shares":689874047,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 16, 2020, the reporting person disposed of all its shares of common stock of the Issuer in connection with the spin-off of the Issuer from the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-031144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000089924320031144/doc4.xml","form_type":"4"}},{"id":383928,"issuer":{"id":3277,"kind":"organization","name":"Viatris Inc","symbol":"VTRS"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.01 per share","published_at":"2020-11-16T22:23:34.000Z","date":"2020-11-13","kind":"other","acquired":true,"shares":689873947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 13, 2020, the reporting person acquired 689,873,947 shares of common stock of the Issuer as partial consideration for the contribution by the reporting person of certain assets and liabilities related to the reporting person's global, primarily off-patent branded and generic established medicines business to the Issuer."}],"balance_after":689874047,"source":{"system":"sec-edgar","filing":"0000899243-20-031144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000089924320031144/doc4.xml","form_type":"4"}},{"id":384547,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-29T21:44:46.000Z","date":"2020-10-27","kind":"purchase","acquired":true,"shares":1200000,"price":10,"value":12000000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 27, 2020, Pfizer Inc. purchased 1,200,000 shares of the Common Stock of Cerevel Therapeutics Holdings, Inc. (f/k/a ARYA Sciences Acquisition Corp II, the \"Issuer\") from the Issuer at a price of $10.00 per share in a private investment in public equity (PIPE) financing."}],"balance_after":27349211,"source":{"system":"sec-edgar","filing":"0000078003-20-000067","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000067/primary_doc.xml","form_type":"4"}},{"id":389763,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":2,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":3,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-04T20:25:17.000Z","date":"2020-06-03","kind":"sale","acquired":false,"shares":370000,"price":40.18,"value":14866600.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All of the shares disposed of were sold by Pfizer Inc. (\"Pfizer\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 2,410,071 shares held of record by Pfizer Ventures (US) LLC, a controlled affiliate of Pfizer, 254,205 shares held of record by Pfizer, and 215,697 shares held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":2879973,"source":{"system":"sec-edgar","filing":"0000078003-20-000038","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000038/primary_doc.xml","form_type":"4"}},{"id":393037,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-16T23:15:07.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":1894444,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pfizer Ventures (US) LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each reporting person disclaims ownership of securities held by each other reporting person, except to the extent of its respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":300752},"source":{"system":"sec-edgar","filing":"0000078003-20-000023","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000023/primary_doc.xml","form_type":"4"}},{"id":393036,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-03-16T23:15:07.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":5470492,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pfizer Ventures (US) LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On March 16, 2020, each share of Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 16, 2020, each share of Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 16, 2020, each share of Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each reporting person disclaims ownership of securities held by each other reporting person, except to the extent of its respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":868467},"source":{"system":"sec-edgar","filing":"0000078003-20-000023","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000023/primary_doc.xml","form_type":"4"}},{"id":393035,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2020-03-16T23:15:07.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":478749,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On March 16, 2020, each share of Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series Seed Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 16, 2020, each share of Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series Seed Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 16, 2020, each share of Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series Seed Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each reporting person disclaims ownership of securities held by each other reporting person, except to the extent of its respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":76003},"source":{"system":"sec-edgar","filing":"0000078003-20-000023","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000023/primary_doc.xml","form_type":"4"}},{"id":393034,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T23:15:07.000Z","date":"2020-03-16","kind":"purchase","acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":false,"nature":"By Pfizer Ventures (US) LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pfizer Ventures (US) LLC purchased 312,500 additional shares of common stock in the Issuer's initial public offering at the initial public offering price of $16.00 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each reporting person disclaims ownership of securities held by each other reporting person, except to the extent of its respective pecuniary interest therein."}],"balance_after":1481719,"source":{"system":"sec-edgar","filing":"0000078003-20-000023","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000023/primary_doc.xml","form_type":"4"}},{"id":393033,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T23:15:07.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":300752,"ownership":{"direct":false,"nature":"By Pfizer Ventures (US) LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each reporting person disclaims ownership of securities held by each other reporting person, except to the extent of its respective pecuniary interest therein."}],"balance_after":1169219,"source":{"system":"sec-edgar","filing":"0000078003-20-000023","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000023/primary_doc.xml","form_type":"4"}},{"id":393032,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T23:15:07.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":868467,"ownership":{"direct":false,"nature":"By Pfizer Ventures (US) LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 16, 2020, each share of Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each reporting person disclaims ownership of securities held by each other reporting person, except to the extent of its respective pecuniary interest therein."}],"balance_after":868467,"source":{"system":"sec-edgar","filing":"0000078003-20-000023","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000023/primary_doc.xml","form_type":"4"}},{"id":393031,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T23:15:07.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":76003,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 16, 2020, each share of Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series Seed Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each reporting person disclaims ownership of securities held by each other reporting person, except to the extent of its respective pecuniary interest therein."}],"balance_after":76003,"source":{"system":"sec-edgar","filing":"0000078003-20-000023","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000023/primary_doc.xml","form_type":"4"}},{"id":400180,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2019-09-19T20:19:11.000Z","date":"2019-09-17","kind":"exercise","acquired":false,"shares":3465571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series B Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer (\"PVUS\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series B Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer (\"PVUS\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series B Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer (\"PVUS\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series B Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer (\"PVUS\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":526602},"source":{"system":"sec-edgar","filing":"0000078003-19-000071","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000071/primary_doc.xml","form_type":"4"}},{"id":400179,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-09-19T20:19:11.000Z","date":"2019-09-17","kind":"exercise","acquired":false,"shares":20000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each share of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3039051},"source":{"system":"sec-edgar","filing":"0000078003-19-000071","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000071/primary_doc.xml","form_type":"4"}},{"id":400178,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Junior Series A Convertible Preferred Stock","published_at":"2019-09-19T20:19:11.000Z","date":"2019-09-17","kind":"exercise","acquired":false,"shares":6437500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Junior Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Junior Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Inc. (\"Pfizer\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Junior Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Junior Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Inc. (\"Pfizer\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Junior Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Junior Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Inc. (\"Pfizer\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Junior Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Junior Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Inc. (\"Pfizer\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":978194},"source":{"system":"sec-edgar","filing":"0000078003-19-000071","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000071/primary_doc.xml","form_type":"4"}},{"id":400177,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-19T20:19:11.000Z","date":"2019-09-17","kind":"purchase","acquired":true,"shares":50000,"price":18,"value":900000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"PVUS purchased such additional shares of Common Stock in the Issuer's initial public offering at the initial public offering price of $18.00 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein."}],"balance_after":4593847,"source":{"system":"sec-edgar","filing":"0000078003-19-000071","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000071/primary_doc.xml","form_type":"4"}},{"id":400176,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-19T20:19:11.000Z","date":"2019-09-17","kind":"exercise","acquired":true,"shares":526602,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series B Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer (\"PVUS\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series B Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer (\"PVUS\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein."}],"balance_after":4543847,"source":{"system":"sec-edgar","filing":"0000078003-19-000071","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000071/primary_doc.xml","form_type":"4"}},{"id":400175,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-19T20:19:11.000Z","date":"2019-09-17","kind":"exercise","acquired":true,"shares":3039051,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each share of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein."}],"balance_after":4017245,"source":{"system":"sec-edgar","filing":"0000078003-19-000071","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000071/primary_doc.xml","form_type":"4"}},{"id":400174,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-19T20:19:11.000Z","date":"2019-09-17","kind":"exercise","acquired":true,"shares":978194,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of Junior Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Junior Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Inc. (\"Pfizer\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Junior Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Junior Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Inc. (\"Pfizer\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein."}],"balance_after":978194,"source":{"system":"sec-edgar","filing":"0000078003-19-000071","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000071/primary_doc.xml","form_type":"4"}},{"id":403255,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":624205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":624205},"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403254,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":215697,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":215697},"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403253,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":2360071,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2360071},"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403252,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"purchase","acquired":true,"shares":50000,"price":17,"value":850000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"PVUS purchased 50,000 additional shares of common stock in the Issuer's initial public offering for consideration of $17.00 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":3249973,"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403251,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":624205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":3199973,"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403250,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":215697,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":2575768,"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403249,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":2360071,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":2360071,"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":410633,"issuer":{"id":2385,"kind":"organization","name":"ICU MEDICAL INC/DE","symbol":"ICUI"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":16047,"kind":"person","name":"C.P. Pharmaceuticals International C.V.","position":2,"cik":"0001697389","reported_name":"C.P. Pharmaceuticals International C.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Note (1)"}},{"id":16048,"kind":"organization","name":"Pfizer Production LLC","position":3,"cik":"0001697379","reported_name":"Pfizer Production LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Note (1)"}},{"id":16049,"kind":"organization","name":"Pfizer Manufacturing LLC","position":4,"cik":"0001697471","reported_name":"Pfizer Manufacturing LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Note (1)"}}],"security":"Common Stock","published_at":"2018-11-16T21:50:55.000Z","date":"2018-11-15","kind":"sale","acquired":false,"shares":2500000,"price":209.25,"value":523125000.0,"ownership":{"direct":false,"nature":"-"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares were owned directly by C.P. Pharmaceuticals International C.V. (\"CPPI\"), whose general partners are Pfizer Production LLC (\"PPL\") and Pfizer Manufacturing LLC (\"PPM\"). CPPI, PPL and PPM are indirect wholly-owned subsidiaries of Pfizer Inc. (\"Pfizer\"). Pfizer, PPL and PPM were indirect beneficial owners of the shares, but each of PPL and PML, as a general partner of CPPI, disclaims ownership of securities held by CPPI except to the extent of any pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares were owned directly by C.P. Pharmaceuticals International C.V. (\"CPPI\"), whose general partners are Pfizer Production LLC (\"PPL\") and Pfizer Manufacturing LLC (\"PPM\"). CPPI, PPL and PPM are indirect wholly-owned subsidiaries of Pfizer Inc. (\"Pfizer\"). Pfizer, PPL and PPM were indirect beneficial owners of the shares, but each of PPL and PML, as a general partner of CPPI, disclaims ownership of securities held by CPPI except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares were owned directly by C.P. Pharmaceuticals International C.V. (\"CPPI\"), whose general partners are Pfizer Production LLC (\"PPL\") and Pfizer Manufacturing LLC (\"PPM\"). CPPI, PPL and PPM are indirect wholly-owned subsidiaries of Pfizer Inc. (\"Pfizer\"). Pfizer, PPL and PPM were indirect beneficial owners of the shares, but each of PPL and PML, as a general partner of CPPI, disclaims ownership of securities held by CPPI except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000078003-18-000095","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800318000095/primary_doc.xml","form_type":"4"}},{"id":411291,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2018-10-17T21:17:16.000Z","date":"2018-10-15","kind":"exercise","acquired":false,"shares":4185997,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of the Issuer's Series A-1 Convertible Preferred Stock (the \"Preferred Stock\") converted into the Issuer's common stock on a 1-for-5.25 basis without payment or consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of the Issuer's Series A-1 Convertible Preferred Stock (the \"Preferred Stock\") converted into the Issuer's common stock on a 1-for-5.25 basis without payment or consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of the Issuer's Series A-1 Convertible Preferred Stock (the \"Preferred Stock\") converted into the Issuer's common stock on a 1-for-5.25 basis without payment or consideration. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":21976484},"source":{"system":"sec-edgar","filing":"0000078003-18-000080","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800318000080/primary_doc.xml","form_type":"4"}},{"id":411290,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-17T21:17:16.000Z","date":"2018-10-15","kind":"purchase","acquired":true,"shares":55556,"price":18,"value":1000008.0,"ownership":{"direct":true},"balance_after":22032040,"source":{"system":"sec-edgar","filing":"0000078003-18-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800318000080/primary_doc.xml","form_type":"4"}},{"id":411289,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-17T21:17:16.000Z","date":"2018-10-15","kind":"exercise","acquired":true,"shares":21976484,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of the Issuer's Series A-1 Convertible Preferred Stock (the \"Preferred Stock\") converted into the Issuer's common stock on a 1-for-5.25 basis without payment or consideration. The Preferred Stock had no expiration date."}],"balance_after":21976484,"source":{"system":"sec-edgar","filing":"0000078003-18-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800318000080/primary_doc.xml","form_type":"4"}},{"id":412700,"issuer":{"id":2385,"kind":"organization","name":"ICU MEDICAL INC/DE","symbol":"ICUI"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16047,"kind":"person","name":"C.P. Pharmaceuticals International C.V.","position":2,"cik":"0001697389","reported_name":"C.P. Pharmaceuticals International C.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16048,"kind":"organization","name":"Pfizer Production LLC","position":3,"cik":"0001697379","reported_name":"Pfizer Production LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16049,"kind":"organization","name":"Pfizer Manufacturing LLC","position":4,"cik":"0001697471","reported_name":"Pfizer Manufacturing LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-15T20:33:21.000Z","date":"2018-08-13","kind":"sale","acquired":false,"shares":700000,"price":284.35,"value":199045000.0,"ownership":{"direct":false,"nature":"_"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares are owned directly by C.P. Pharmaceuticals International C.V. (\"CPPI\"), whose general partners are Pfizer Production LLC (\"PPL\") and Pfizer Manufacturing LLC (\"PPM\"). CPPI, PPL and PPM are indirect wholly-owned subsidiaries of Pfizer Inc. (\"Pfizer\"). Pfizer, PPL and PPM are indirect beneficial owners of the shares, but each of PPL and PML, as a general partner of CPPI, disclaims ownership of securities held by CPPI except to the extent of any pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are owned directly by C.P. Pharmaceuticals International C.V. (\"CPPI\"), whose general partners are Pfizer Production LLC (\"PPL\") and Pfizer Manufacturing LLC (\"PPM\"). CPPI, PPL and PPM are indirect wholly-owned subsidiaries of Pfizer Inc. (\"Pfizer\"). Pfizer, PPL and PPM are indirect beneficial owners of the shares, but each of PPL and PML, as a general partner of CPPI, disclaims ownership of securities held by CPPI except to the extent of any pecuniary interest therein."}],"balance_after":2500000,"source":{"system":"sec-edgar","filing":"0000078003-18-000075","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800318000075/primary_doc.xml","form_type":"4"}},{"id":423002,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Junior Preferred Stock","published_at":"2017-10-10T20:22:55.000Z","date":"2017-10-10","kind":"exercise","acquired":false,"shares":940125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the \"Series A Preferred\") and series A-1 junior preferred stock (the \"Series A-1 Preferred\") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration.  The Series A Preferred and the Series A-1 Preferred had no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects the number of shares of Series A Preferred and Series A-1 Preferred, as applicable, held by the Reporting Person on an as-converted to common stock basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the \"Series A Preferred\") and series A-1 junior preferred stock (the \"Series A-1 Preferred\") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration.  The Series A Preferred and the Series A-1 Preferred had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the \"Series A Preferred\") and series A-1 junior preferred stock (the \"Series A-1 Preferred\") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration.  The Series A Preferred and the Series A-1 Preferred had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Reflects the number of shares of Series A Preferred and Series A-1 Preferred, as applicable, held by the Reporting Person on an as-converted to common stock basis."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":940125},"source":{"system":"sec-edgar","filing":"0001104659-17-061575","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/78003/000110465917061575/a4.xml","form_type":"4"}},{"id":423001,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2017-10-10T20:22:55.000Z","date":"2017-10-10","kind":"exercise","acquired":false,"shares":447514,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the \"Series A Preferred\") and series A-1 junior preferred stock (the \"Series A-1 Preferred\") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration.  The Series A Preferred and the Series A-1 Preferred had no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects the number of shares of Series A Preferred and Series A-1 Preferred, as applicable, held by the Reporting Person on an as-converted to common stock basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the \"Series A Preferred\") and series A-1 junior preferred stock (the \"Series A-1 Preferred\") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration.  The Series A Preferred and the Series A-1 Preferred had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the \"Series A Preferred\") and series A-1 junior preferred stock (the \"Series A-1 Preferred\") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration.  The Series A Preferred and the Series A-1 Preferred had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Reflects the number of shares of Series A Preferred and Series A-1 Preferred, as applicable, held by the Reporting Person on an as-converted to common stock basis."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":447514},"source":{"system":"sec-edgar","filing":"0001104659-17-061575","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/78003/000110465917061575/a4.xml","form_type":"4"}},{"id":423000,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-10T20:22:55.000Z","date":"2017-10-10","kind":"purchase","acquired":true,"shares":40000,"price":17,"value":680000.0,"ownership":{"direct":true},"balance_after":1427639,"source":{"system":"sec-edgar","filing":"0001104659-17-061575","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000110465917061575/a4.xml","form_type":"4"}},{"id":422999,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-10T20:22:55.000Z","date":"2017-10-10","kind":"exercise","acquired":true,"shares":940125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the \"Series A Preferred\") and series A-1 junior preferred stock (the \"Series A-1 Preferred\") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration.  The Series A Preferred and the Series A-1 Preferred had no expiration date."}],"balance_after":1387639,"source":{"system":"sec-edgar","filing":"0001104659-17-061575","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000110465917061575/a4.xml","form_type":"4"}},{"id":422998,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-10T20:22:55.000Z","date":"2017-10-10","kind":"exercise","acquired":true,"shares":447514,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the \"Series A Preferred\") and series A-1 junior preferred stock (the \"Series A-1 Preferred\") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration.  The Series A Preferred and the Series A-1 Preferred had no expiration date."}],"balance_after":447514,"source":{"system":"sec-edgar","filing":"0001104659-17-061575","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000110465917061575/a4.xml","form_type":"4"}},{"id":445913,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Series D Convertible Preferred Stock","published_at":"2015-10-07T21:42:24.000Z","date":"2015-10-05","kind":"exercise","acquired":false,"shares":491418,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series C Convertible and Series D Convertible Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis immediately prior to the closing of the issuer's initial public offering, and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series C Convertible and Series D Convertible Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis immediately prior to the closing of the issuer's initial public offering, and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series C Convertible and Series D Convertible Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis immediately prior to the closing of the issuer's initial public offering, and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series C Convertible and Series D Convertible Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis immediately prior to the closing of the issuer's initial public offering, and has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":491418},"source":{"system":"sec-edgar","filing":"0001225208-15-019424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815019424/doc4.xml","form_type":"4"}},{"id":445912,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Series C Convertible Preferred Stock","published_at":"2015-10-07T21:42:24.000Z","date":"2015-10-05","kind":"exercise","acquired":false,"shares":1047806,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series C Convertible and Series D Convertible Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis immediately prior to the closing of the issuer's initial public offering, and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series C Convertible and Series D Convertible Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis immediately prior to the closing of the issuer's initial public offering, and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series C Convertible and Series D Convertible Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis immediately prior to the closing of the issuer's initial public offering, and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series C Convertible and Series D Convertible Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis immediately prior to the closing of the issuer's initial public offering, and has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1047806},"source":{"system":"sec-edgar","filing":"0001225208-15-019424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815019424/doc4.xml","form_type":"4"}},{"id":445911,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-10-07T21:42:24.000Z","date":"2015-10-06","kind":"other","acquired":true,"shares":235855,"price":7,"value":1650985.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reporting person received 235,855 shares of Common Stock as a payment-in-kind dividend in connection with the conversion of the reporting person's Series C Convertible and Series D Convertible Preferred Stock into shares of Common Stock."}],"balance_after":2489364,"source":{"system":"sec-edgar","filing":"0001225208-15-019424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815019424/doc4.xml","form_type":"4"}},{"id":445910,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-10-07T21:42:24.000Z","date":"2015-10-06","kind":"purchase","acquired":true,"shares":714285,"price":7,"value":4999995.0,"ownership":{"direct":true},"balance_after":2253509,"source":{"system":"sec-edgar","filing":"0001225208-15-019424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815019424/doc4.xml","form_type":"4"}},{"id":445909,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-10-07T21:42:24.000Z","date":"2015-10-05","kind":"exercise","acquired":true,"shares":1539224,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series C Convertible and Series D Convertible Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis immediately prior to the closing of the issuer's initial public offering, and has no expiration date."}],"balance_after":1539224,"source":{"system":"sec-edgar","filing":"0001225208-15-019424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815019424/doc4.xml","form_type":"4"}},{"id":447856,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":58632,"price":23.4112,"value":1372645.4784,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $23.00 to $23.99, inclusive."}],"balance_after":975403,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":447855,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":44268,"price":22.5994,"value":1000430.2392,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $22.00 to $22.98, inclusive."}],"balance_after":1034035,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":447854,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":31400,"price":24.3129,"value":763425.06,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $24.00 to $24.90, inclusive."}],"balance_after":1078303,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":447853,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":25931,"price":20.3476,"value":527633.6156,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $20.00 to $20.82, inclusive."}],"balance_after":1109703,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":447852,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":13109,"price":26.3213,"value":345045.9217,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $26.00 to $26.99, inclusive."}],"balance_after":1135634,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":447851,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":12726,"price":25.3233,"value":322264.3158,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $25.00 to $25.99, inclusive."}],"balance_after":1148743,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":447850,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":11627,"price":38.4947,"value":447577.8769,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $38.00 to $38.93, inclusive."}],"balance_after":1161469,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":447849,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":10544,"price":36.3687,"value":383471.5728,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $36.00 to $36.99, inclusive."}],"balance_after":1173096,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":447848,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":9901,"price":37.2264,"value":368578.5864,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $37.00 to $37.90, inclusive."}],"balance_after":1183640,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":447847,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":9142,"price":39.5172,"value":361266.2424,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $39.00 to $39.99, inclusive."}],"balance_after":1193541,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":447846,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":8969,"price":21.4506,"value":192390.4314,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $21.01 to $21.87, inclusive."}],"balance_after":1202683,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":447845,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":8565,"price":27.3561,"value":234304.9965,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $27.00 to $27.90, inclusive."}],"balance_after":1211652,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":447844,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":6073,"price":40.2955,"value":244714.5715,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $40.00 to $40.99, inclusive."}],"balance_after":1220217,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":447843,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":3207,"price":35.6072,"value":114192.2904,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $35.25 to $35.94, inclusive."}],"balance_after":1226290,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":447842,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":2975,"price":28.467,"value":84689.325,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $28.00 to $28.90, inclusive."}],"balance_after":1229497,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":447841,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":2840,"price":41.2475,"value":117142.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $41.00 to $41.46, inclusive.  The reporting person undertakes to provide to Aquinox Pharmaceuticals Inc., the \"Issuer\",  any security holder of the Issuer, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes (1) through (16) to this Form 4."}],"balance_after":1232472,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":447840,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2015-08-12T20:30:18.000Z","date":"2015-08-10","kind":"sale","acquired":false,"shares":18,"price":29,"value":522.0,"ownership":{"direct":true},"balance_after":1235312,"source":{"system":"sec-edgar","filing":"0001225208-15-016754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520815016754/doc4.xml","form_type":"4"}},{"id":466776,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2014-03-14T19:27:19.000Z","date":"2014-03-12","kind":"exercise","acquired":false,"shares":301005,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":301005},"source":{"system":"sec-edgar","filing":"0001209191-14-020601","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919114020601/doc4.xml","form_type":"4"}},{"id":466775,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2014-03-14T19:27:19.000Z","date":"2014-03-12","kind":"exercise","acquired":false,"shares":327178,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":327178},"source":{"system":"sec-edgar","filing":"0001209191-14-020601","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919114020601/doc4.xml","form_type":"4"}},{"id":466774,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2014-03-14T19:27:19.000Z","date":"2014-03-12","kind":"exercise","acquired":false,"shares":334420,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":334420},"source":{"system":"sec-edgar","filing":"0001209191-14-020601","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919114020601/doc4.xml","form_type":"4"}},{"id":466773,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-03-14T19:27:19.000Z","date":"2014-03-12","kind":"purchase","acquired":true,"shares":272727,"price":11,"value":2999997.0,"ownership":{"direct":true},"balance_after":1235330,"source":{"system":"sec-edgar","filing":"0001209191-14-020601","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919114020601/doc4.xml","form_type":"4"}},{"id":466772,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-03-14T19:27:19.000Z","date":"2014-03-12","kind":"exercise","acquired":true,"shares":962603,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date."}],"balance_after":962603,"source":{"system":"sec-edgar","filing":"0001209191-14-020601","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919114020601/doc4.xml","form_type":"4"}},{"id":468354,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2014-02-20T19:51:57.000Z","date":"2014-02-18","kind":"exercise","acquired":false,"shares":1904905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Every 8.13 shares of Series B Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Every 8.13 shares of Series B Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Every 8.13 shares of Series B Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Every 8.13 shares of Series B Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":234306},"source":{"system":"sec-edgar","filing":"0001209191-14-012241","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919114012241/doc4.xml","form_type":"4"}},{"id":468353,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2014-02-20T19:51:57.000Z","date":"2014-02-18","kind":"exercise","acquired":false,"shares":11812438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Every 8.13 shares of Series A Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Every 8.13 shares of Series A Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Every 8.13 shares of Series A Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Every 8.13 shares of Series A Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1452944},"source":{"system":"sec-edgar","filing":"0001209191-14-012241","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919114012241/doc4.xml","form_type":"4"}},{"id":468352,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-02-20T19:51:57.000Z","date":"2014-02-18","kind":"exercise","acquired":true,"shares":234306,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Every 8.13 shares of Series B Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."}],"balance_after":1687250,"source":{"system":"sec-edgar","filing":"0001209191-14-012241","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919114012241/doc4.xml","form_type":"4"}},{"id":468351,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-02-20T19:51:57.000Z","date":"2014-02-18","kind":"exercise","acquired":true,"shares":1452944,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Every 8.13 shares of Series A Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."}],"balance_after":1452944,"source":{"system":"sec-edgar","filing":"0001209191-14-012241","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919114012241/doc4.xml","form_type":"4"}},{"id":469443,"issuer":{"id":16554,"kind":"organization","name":"Eiger BioPharmaceuticals, Inc.","symbol":"EIGR"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Warrants","published_at":"2014-02-06T20:53:40.000Z","date":"2014-02-04","kind":"exercise","acquired":true,"shares":42659,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the automatic conversion of Series A-1 Preferred Warrants into Common Stock Warrants on a 1-for-12.49 basis upon the closing of the Issuer's initial public offering."}],"balance_after":42659,"derivative":{"exercise_price":5.61,"exercise_date":"2013-10-15","expiration_date":"2018-10-15","underlying":"Common Stock","underlying_shares":42659},"source":{"system":"sec-edgar","filing":"0001209191-14-007978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919114007978/doc4.xml","form_type":"4"}},{"id":469442,"issuer":{"id":16554,"kind":"organization","name":"Eiger BioPharmaceuticals, Inc.","symbol":"EIGR"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Warrants","published_at":"2014-02-06T20:53:40.000Z","date":"2014-02-04","kind":"exercise","acquired":false,"shares":532818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the automatic conversion of Series A-1 Preferred Warrants into Common Stock Warrants on a 1-for-12.49 basis upon the closing of the Issuer's initial public offering."}],"balance_after":0,"derivative":{"exercise_price":0.449,"exercise_date":"2013-10-15","expiration_date":"2018-10-15","underlying":"Series A-1 Preferred Stock","underlying_shares":532818},"source":{"system":"sec-edgar","filing":"0001209191-14-007978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919114007978/doc4.xml","form_type":"4"}},{"id":469441,"issuer":{"id":16554,"kind":"organization","name":"Eiger BioPharmaceuticals, Inc.","symbol":"EIGR"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Notes","published_at":"2014-02-06T20:53:40.000Z","date":"2014-02-04","kind":"exercise","acquired":false,"shares":23145,"price":8,"value":185160.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Automatic conversion, in connection with the Issuer's initial public offering, of convertible promissory notes, including principal and accrued interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Automatic conversion, in connection with the Issuer's initial public offering, of convertible promissory notes, including principal and accrued interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Automatic conversion, in connection with the Issuer's initial public offering, of convertible promissory notes, including principal and accrued interest."}],"balance_after":0,"derivative":{"exercise_price":8,"underlying":"Common Stock","underlying_shares":23145},"source":{"system":"sec-edgar","filing":"0001209191-14-007978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919114007978/doc4.xml","form_type":"4"}},{"id":469440,"issuer":{"id":16554,"kind":"organization","name":"Eiger BioPharmaceuticals, Inc.","symbol":"EIGR"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2014-02-06T20:53:40.000Z","date":"2014-02-04","kind":"exercise","acquired":false,"shares":19289531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Every 12.49 shares of Series A-1 Preferred Stock automatically converted into 1 share of Common Stock  without payment of further consideration upon the closing of the Issuer's initial public offering.  The shares have no expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"Every 12.49 shares of Series A-1 Preferred Stock automatically converted into 1 share of Common Stock  without payment of further consideration upon the closing of the Issuer's initial public offering.  The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Every 12.49 shares of Series A-1 Preferred Stock automatically converted into 1 share of Common Stock  without payment of further consideration upon the closing of the Issuer's initial public offering.  The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Every 12.49 shares of Series A-1 Preferred Stock automatically converted into 1 share of Common Stock  without payment of further consideration upon the closing of the Issuer's initial public offering.  The shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1544397},"source":{"system":"sec-edgar","filing":"0001209191-14-007978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919114007978/doc4.xml","form_type":"4"}},{"id":469439,"issuer":{"id":16554,"kind":"organization","name":"Eiger BioPharmaceuticals, Inc.","symbol":"EIGR"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-02-06T20:53:40.000Z","date":"2014-02-04","kind":"purchase","acquired":true,"shares":227261,"price":8,"value":1818088.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares were purchased at the Issuer's initial public offering."}],"balance_after":1794803,"source":{"system":"sec-edgar","filing":"0001209191-14-007978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919114007978/doc4.xml","form_type":"4"}},{"id":469438,"issuer":{"id":16554,"kind":"organization","name":"Eiger BioPharmaceuticals, Inc.","symbol":"EIGR"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-02-06T20:53:40.000Z","date":"2014-02-04","kind":"exercise","acquired":true,"shares":23145,"price":8,"value":185160.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Automatic conversion, in connection with the Issuer's initial public offering, of convertible promissory notes, including principal and accrued interest."}],"balance_after":1567542,"source":{"system":"sec-edgar","filing":"0001209191-14-007978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919114007978/doc4.xml","form_type":"4"}},{"id":469437,"issuer":{"id":16554,"kind":"organization","name":"Eiger BioPharmaceuticals, Inc.","symbol":"EIGR"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2014-02-06T20:53:40.000Z","date":"2014-02-04","kind":"exercise","acquired":true,"shares":1544397,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Every 12.49 shares of Series A-1 Preferred Stock automatically converted into 1 share of Common Stock  without payment of further consideration upon the closing of the Issuer's initial public offering.  The shares have no expiration date."}],"balance_after":1544397,"source":{"system":"sec-edgar","filing":"0001209191-14-007978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919114007978/doc4.xml","form_type":"4"}},{"id":476417,"issuer":{"id":679,"kind":"organization","name":"Zoetis Inc.","symbol":"ZTS"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Common Stock","published_at":"2013-06-26T21:17:37.000Z","date":"2013-06-24","kind":"exercise","acquired":false,"shares":400985000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Class B Common Stock was convertible into Class A Common Stock at any time on a one-for-one basis and had no exercise or conversion price or expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Class B Common Stock was convertible into Class A Common Stock at any time on a one-for-one basis and had no exercise or conversion price or expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Class B Common Stock was convertible into Class A Common Stock at any time on a one-for-one basis and had no exercise or conversion price or expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":400985000},"source":{"system":"sec-edgar","filing":"0000078003-13-000014","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800313000014/primary_doc.xml","form_type":"4"}},{"id":476416,"issuer":{"id":679,"kind":"organization","name":"Zoetis Inc.","symbol":"ZTS"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2013-06-26T21:17:37.000Z","date":"2013-06-24","kind":"other","acquired":false,"shares":400985000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pfizer Inc. (\"Pfizer\") disposed of 400,985,000 shares of Class A Common Stock of Zoetis Inc. (\"Class A Common Stock\") in exchange for 405,117,195 shares of Pfizer common stock pursuant to a registered exchange offer to Pfizer common stockholders. The final exchange ratio for the exchange offer was 0.9898 shares of Class A Common Stock per share of Pfizer common stock accepted in the exchange offer. As a result of the exchange offer, Pfizer has disposed of its entire equity interest in the Issuer. The closing price of Pfizer common stock on the New York Stock Exchange on June 21, 2013, the trading day immediately preceding the day on which Pfizer accepted Pfizer shares that had been validly tendered and not validly withdrawn,was $28.46."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000078003-13-000014","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800313000014/primary_doc.xml","form_type":"4"}},{"id":476415,"issuer":{"id":679,"kind":"organization","name":"Zoetis Inc.","symbol":"ZTS"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2013-06-26T21:17:37.000Z","date":"2013-06-24","kind":"exercise","acquired":true,"shares":400985000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Class A Common Stock was acquired pursuant to the conversion of Class B Common Stock in an exempt transaction under Rule 16b-6(b). The Class B Common Stock was converted into Class A Common Stock on a one-for-one basis and had no exercise or conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Class B Common Stock was convertible into Class A Common Stock at any time on a one-for-one basis and had no exercise or conversion price or expiration date."}],"balance_after":400985000,"source":{"system":"sec-edgar","filing":"0000078003-13-000014","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800313000014/primary_doc.xml","form_type":"4"}},{"id":482266,"issuer":{"id":679,"kind":"organization","name":"Zoetis Inc.","symbol":"ZTS"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Common Stock","published_at":"2013-02-08T21:19:51.000Z","date":"2013-02-06","kind":"exercise","acquired":false,"shares":12915000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Class B Common Stock held by Pfizer Inc. or one of its subsidiaries will be convertible into one share of Class A Common Stock at any time but will not be convertible if held by any other holder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Class B Common Stock held by Pfizer Inc. or one of its subsidiaries will be convertible into one share of Class A Common Stock at any time but will not be convertible if held by any other holder."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Class B Common Stock held by Pfizer Inc. or one of its subsidiaries will be convertible into one share of Class A Common Stock at any time but will not be convertible if held by any other holder."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pfizer Inc. may be deemed a director of the Issuer on the basis of its relationship with five of the directors of the Issuer."}],"balance_after":400985000,"derivative":{"underlying":"Class A Common Stock","underlying_shares":12915000},"source":{"system":"sec-edgar","filing":"0001209191-13-007372","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919113007372/doc4.xml","form_type":"4"}},{"id":482265,"issuer":{"id":679,"kind":"organization","name":"Zoetis Inc.","symbol":"ZTS"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2013-02-08T21:19:51.000Z","date":"2013-02-06","kind":"sale","acquired":false,"shares":99015000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pfizer Inc. disposed of 99,015,000 shares of Class A Common Stock in exchange for outstanding debt obligations of Pfizer Inc.  The debt obligations were valued at their fair market value, and the fair market value of the debt obligations exchanged equaled $25.038 per share of Class A Common Stock exchanged."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pfizer Inc. may be deemed a director of the Issuer on the basis of its relationship with five of the directors of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-13-007372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919113007372/doc4.xml","form_type":"4"}},{"id":482264,"issuer":{"id":679,"kind":"organization","name":"Zoetis Inc.","symbol":"ZTS"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2013-02-08T21:19:51.000Z","date":"2013-02-06","kind":"exercise","acquired":true,"shares":12915000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Class A Common Stock was acquired pursuant to the conversion of Class B Common Stock in an exempt transaction under the Exchange Act Rule 16b-6(b). The Class B Common Stock was converted into Class A Common Stock on a one-for-one basis and had no exercise or conversion price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pfizer Inc. may be deemed a director of the Issuer on the basis of its relationship with five of the directors of the Issuer."}],"balance_after":12915000,"source":{"system":"sec-edgar","filing":"0001209191-13-007372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000120919113007372/doc4.xml","form_type":"4"}},{"id":500015,"issuer":{"id":13934,"kind":"organization","name":"ICAGEN INC","symbol":"ICGN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16835,"kind":"organization","name":"Eclipse Acquisition Corp.","position":2,"cik":"0001529320","reported_name":"Eclipse Acquisition Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2011-11-02T23:16:21.000Z","date":"2011-10-27","kind":"purchase","acquired":true,"shares":2743269,"price":6,"value":16459614.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amount reflects all of the outstanding shares of Icagen, Inc. (\"Icagen\") not owned by Pfizer Inc. (\"Pfizer\") and Eclipse Acquisition Corp.  On October 27, 2011, Eclipse Acquisition Corp. was merged with and into Icagen with Icagen continuing as the surviving corporation and a wholly-owned subsidiary of Pfizer.  At the effective time of the merger, these shares of common stock were cancelled and ceased to exist."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Prior to the merger, Pfizer held 100 shares of common stock, $0.01 par value per share, of Eclipse Acquisition Corp., which represented all of the issued and outstanding capital stock of Eclipse Acquisition Corp.  At the effective time of the merger, each share of Eclipse Acquisition Corp. was converted into one share of common stock of Icagen, resulting in the acquisition by Pfizer of 100% of the equity interest of Icagen."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0000078003-11-000018","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800311000018/primary_doc.xml","form_type":"4"}},{"id":500859,"issuer":{"id":13934,"kind":"organization","name":"ICAGEN INC","symbol":"ICGN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16835,"kind":"organization","name":"Eclipse Acquisition Corp.","position":2,"cik":"0001529320","reported_name":"Eclipse Acquisition Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2011-09-20T19:06:59.000Z","date":"2011-09-19","kind":"purchase","acquired":true,"shares":61083,"price":6,"value":366498.0,"ownership":{"direct":false,"nature":"FN"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are directly owned by Eclipse Acquisition Corp., a wholly owned subsidiary of Pfizer Inc."}],"balance_after":5393380,"source":{"system":"sec-edgar","filing":"0000078003-11-000017","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800311000017/primary_doc.xml","form_type":"4"}},{"id":500858,"issuer":{"id":13934,"kind":"organization","name":"ICAGEN INC","symbol":"ICGN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16835,"kind":"organization","name":"Eclipse Acquisition Corp.","position":2,"cik":"0001529320","reported_name":"Eclipse Acquisition Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2011-09-20T19:06:59.000Z","date":"2011-09-16","kind":"purchase","acquired":true,"shares":5536,"price":6,"value":33216.0,"ownership":{"direct":false,"nature":"FN"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are directly owned by Eclipse Acquisition Corp., a wholly owned subsidiary of Pfizer Inc."}],"balance_after":5332297,"source":{"system":"sec-edgar","filing":"0000078003-11-000017","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800311000017/primary_doc.xml","form_type":"4"}},{"id":500933,"issuer":{"id":13934,"kind":"organization","name":"ICAGEN INC","symbol":"ICGN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16835,"kind":"organization","name":"Eclipse Acquisition Corp.","position":2,"cik":"0001529320","reported_name":"Eclipse Acquisition Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2011-09-16T22:01:17.000Z","date":"2011-09-15","kind":"purchase","acquired":true,"shares":232203,"price":6,"value":1393218.0,"ownership":{"direct":false,"nature":"FN"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are directly owned by Eclipse Acquisition Corp., a wholly owned subsidiary of Pfizer Inc."}],"balance_after":5326761,"source":{"system":"sec-edgar","filing":"0000078003-11-000016","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800311000016/primary_doc.xml","form_type":"4"}},{"id":500934,"issuer":{"id":13934,"kind":"organization","name":"ICAGEN INC","symbol":"ICGN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2011-09-16T21:22:26.000Z","date":"2011-09-02","kind":"purchase","acquired":true,"shares":4611921,"price":6,"value":27671526.0,"ownership":{"direct":false,"nature":"by Eclipse Acquisition Corp."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This filing is being amended to adjust the number of shares of Common Stock (hereinafter defined) acquired as reported in Table I, Box 4 and the number of shares of Common Stock beneficially owned as reported in Table I, Box 5 which were previously reported as 4,617,045. The adjusted amount for each of Box 4 and Box 5 of Table I is 4,611,921."},{"field":"shares","element":"transactionShares","label":"F2","text":"This adjustment results from the failure of certain shareholders to deliver 5,124 shares of Common Stock tendered pursuant to notices of guaranteed delivery, as executed in conjunction with a tender offer by Eclipse Acquisition Corp. (\"Purchaser\"), a wholly-owned subsidiary of Pfizer Inc. (\"Parent\"), for all of the issued and outstanding common stock, $0.001 par value per share (the \"Common Stock\") of Icagen, Inc."}],"balance_after":4611921,"source":{"system":"sec-edgar","filing":"0000078003-11-000014","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800311000014/primary_doc.xml","form_type":"4/A","original_submission_date":"2011-09-07"}},{"id":501021,"issuer":{"id":13934,"kind":"organization","name":"ICAGEN INC","symbol":"ICGN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16835,"kind":"organization","name":"Eclipse Acquisition Corp.","position":2,"cik":"0001529320","reported_name":"Eclipse Acquisition Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2011-09-14T23:25:53.000Z","date":"2011-09-12","kind":"purchase","acquired":true,"shares":422023,"price":6,"value":2532138.0,"ownership":{"direct":false,"nature":"FN"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are directly owned by Eclipse Acquisition Corp., a wholly owned subsidiary of Pfizer Inc."}],"balance_after":5094558,"source":{"system":"sec-edgar","filing":"0000078003-11-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800311000013/primary_doc.xml","form_type":"4"}},{"id":501056,"issuer":{"id":13934,"kind":"organization","name":"ICAGEN INC","symbol":"ICGN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16835,"kind":"organization","name":"Eclipse Acquisition Corp.","position":2,"cik":"0001529320","reported_name":"Eclipse Acquisition Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2011-09-12T17:27:03.000Z","date":"2011-09-09","kind":"purchase","acquired":true,"shares":60121,"price":6,"value":360726.0,"ownership":{"direct":false,"nature":"FN"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are directly owned by Eclipse Acquisition Corp., a wholly owned subsidiary of Pfizer Inc."}],"balance_after":4677659,"source":{"system":"sec-edgar","filing":"0000078003-11-000012","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800311000012/primary_doc.xml","form_type":"4"}},{"id":501055,"issuer":{"id":13934,"kind":"organization","name":"ICAGEN INC","symbol":"ICGN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16835,"kind":"organization","name":"Eclipse Acquisition Corp.","position":2,"cik":"0001529320","reported_name":"Eclipse Acquisition Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2011-09-12T17:27:03.000Z","date":"2011-09-08","kind":"purchase","acquired":true,"shares":493,"price":6,"value":2958.0,"ownership":{"direct":false,"nature":"FN"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are directly owned by Eclipse Acquisition Corp., a wholly owned subsidiary of Pfizer Inc."}],"balance_after":4617538,"source":{"system":"sec-edgar","filing":"0000078003-11-000012","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800311000012/primary_doc.xml","form_type":"4"}},{"id":501135,"issuer":{"id":13934,"kind":"organization","name":"ICAGEN INC","symbol":"ICGN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2011-09-07T22:59:23.000Z","date":"2011-09-02","kind":"purchase","acquired":true,"shares":4617045,"price":6,"value":27702270.0,"ownership":{"direct":false,"nature":"by  Eclipse Acquisition Corp"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares purchased (including approximately 688,100 shares subject to guarantees of delivery) by Eclipse Acquisition Corp. (\"Purchaser\"), a wholly-owned subsidiary of Pfizer Inc. (\"Parent\"), in a tender offer.  These shares are owned directly by Purchaser and may also be deemed to be indirectly beneficially owned by Parent."}],"balance_after":4617045,"source":{"system":"sec-edgar","filing":"0000078003-11-000011","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800311000011/primary_doc.xml","form_type":"4"}},{"id":551329,"issuer":{"id":17165,"kind":"organization","name":"ENCYSIVE PHARMACEUTICALS INC","symbol":"ENCY"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2008-04-16T00:40:28.000Z","date":"2008-04-14","kind":"purchase","acquired":true,"shares":1232412,"price":2.35,"value":2896168.2,"ownership":{"direct":false,"nature":"FN"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are directly owned by Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer Inc."}],"balance_after":69076466,"source":{"system":"sec-edgar","filing":"0000909518-08-000350","document":"pfizer_form4ex.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000090951808000350/pfizer_form4ex.xml","form_type":"4"}},{"id":551328,"issuer":{"id":17165,"kind":"organization","name":"ENCYSIVE PHARMACEUTICALS INC","symbol":"ENCY"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2008-04-16T00:40:28.000Z","date":"2008-04-11","kind":"purchase","acquired":true,"shares":155499,"price":2.35,"value":365422.65,"ownership":{"direct":false,"nature":"FN"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are directly owned by Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer Inc."}],"balance_after":67844054,"source":{"system":"sec-edgar","filing":"0000909518-08-000350","document":"pfizer_form4ex.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000090951808000350/pfizer_form4ex.xml","form_type":"4"}},{"id":551564,"issuer":{"id":17165,"kind":"organization","name":"ENCYSIVE PHARMACEUTICALS INC","symbol":"ENCY"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2008-04-11T19:57:31.000Z","date":"2008-04-10","kind":"purchase","acquired":true,"shares":210794,"price":2.35,"value":495365.9,"ownership":{"direct":false,"nature":"FN"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are directly owned by Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer Inc."}],"balance_after":67688555,"source":{"system":"sec-edgar","filing":"0000909518-08-000336","document":"pfizer_form4ex.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000090951808000336/pfizer_form4ex.xml","form_type":"4"}},{"id":551563,"issuer":{"id":17165,"kind":"organization","name":"ENCYSIVE PHARMACEUTICALS INC","symbol":"ENCY"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2008-04-11T19:57:31.000Z","date":"2008-04-09","kind":"purchase","acquired":true,"shares":12628,"price":2.35,"value":29675.8,"ownership":{"direct":false,"nature":"FN"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are directly owned by Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer Inc."}],"balance_after":67477761,"source":{"system":"sec-edgar","filing":"0000909518-08-000336","document":"pfizer_form4ex.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000090951808000336/pfizer_form4ex.xml","form_type":"4"}},{"id":551800,"issuer":{"id":17165,"kind":"organization","name":"ENCYSIVE PHARMACEUTICALS INC","symbol":"ENCY"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2008-04-09T20:37:13.000Z","date":"2008-04-08","kind":"purchase","acquired":true,"shares":29407,"price":2.35,"value":69106.45,"ownership":{"direct":false,"nature":"FN"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are directly owned by Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer Inc."}],"balance_after":67465133,"source":{"system":"sec-edgar","filing":"0000909518-08-000331","document":"pfizer_form4ex.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000090951808000331/pfizer_form4ex.xml","form_type":"4"}},{"id":551799,"issuer":{"id":17165,"kind":"organization","name":"ENCYSIVE PHARMACEUTICALS INC","symbol":"ENCY"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2008-04-09T20:37:13.000Z","date":"2008-04-07","kind":"purchase","acquired":true,"shares":2203420,"price":2.35,"value":5178037.0,"ownership":{"direct":false,"nature":"FN"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are directly owned by Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer Inc."}],"balance_after":67435726,"source":{"system":"sec-edgar","filing":"0000909518-08-000331","document":"pfizer_form4ex.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000090951808000331/pfizer_form4ex.xml","form_type":"4"}},{"id":552061,"issuer":{"id":17165,"kind":"organization","name":"ENCYSIVE PHARMACEUTICALS INC","symbol":"ENCY"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2008-04-07T22:28:35.000Z","date":"2008-04-04","kind":"purchase","acquired":true,"shares":576170,"price":2.35,"value":1353999.5,"ownership":{"direct":false,"nature":"FN"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are directly owned by Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer Inc."}],"balance_after":65232306,"source":{"system":"sec-edgar","filing":"0000909518-08-000325","document":"pfizer_form4ex.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000090951808000325/pfizer_form4ex.xml","form_type":"4"}}],"next_cursor":"2008-04-07T22:28:35.000000Z,552061"}